The UK's GW Pharmaceuticals has reported positive results from a placebo-controlled "randomized-withdrawal" study of its cannabis mouth spray, Sativex, in patients with neuropathic pain due to multiple sclerosis.
According to the firm, regulators have said that the study design is enough to satisfy the need for long-term efficacy data. This randomized withdrawal study evaluated 42 MS patients with central neuropathic pain who had previously been in a Sativex late-stage MS neuropathic pain study, who continued to take it on an open-label basis for 12 weeks.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze